These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6276789)

  • 21. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 22. Human blood platelet behaviour after inhibition of thromboxane synthetase.
    Heptinstall S; Fox SC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):31S-37S. PubMed ID: 6401998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of thromboxane A2 in regulating porcine basilar arterial tone.
    Miyamoto A; Nakamoto T; Matsuoka Y; Ishiguro S; Nishio A
    J Vet Pharmacol Ther; 1998 Jun; 21(3):223-7. PubMed ID: 9673964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-thromboxane A2 actions of pinane thromboxane A2 derivatives.
    Roth DM; Lefer AM; Smith JB; Nicolaou KC
    Prostaglandins Leukot Med; 1982 Nov; 9(5):503-9. PubMed ID: 6960376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
    Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human platelet thromboxane synthetase by 11a-carbathromboxane A2 analogs.
    Gorman RR; Maxey KM; Bundy GL
    Biochem Biophys Res Commun; 1981 May; 100(1):184-90. PubMed ID: 7196228
    [No Abstract]   [Full Text] [Related]  

  • 28. Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle.
    Saussy DL; Mais DE; Knapp DR; Halushka PV
    Circulation; 1985 Dec; 72(6):1202-7. PubMed ID: 2998641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiological concentrations of epinephrine potentiate thromboxane A2 release from platelets in the isolated rat heart.
    Purchase M; Dusting GJ; Li DM; Read MA
    Circ Res; 1986 Jan; 58(1):172-6. PubMed ID: 3080260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Actions of a novel thromboxane A2-receptor antagonist, S-145, on isolated monkey and cat arteries.
    Nakajima M; Ueda M
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):502-9. PubMed ID: 2476633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
    Smith EF
    Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L; Fitzgerald DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
    Fiddler GI; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM; Jones RL; Wilson NH; Marr CG
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
    Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboxane A2-induced vascular endothelial cell damage and respiratory smooth muscle cell contraction: inhibition by flunarizine, a Ca2+-overload blocker.
    De Clerck F; Loots W; Somers Y; Van Gorp L; Verheyen A; Wouters L
    Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):4-23. PubMed ID: 2990365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed.
    McMahon TJ; Hood JS; Nossaman BD; Ibrahim IN; Feng CJ; Kadowitz PJ
    J Appl Physiol (1985); 1991 Nov; 71(5):2012-8. PubMed ID: 1837015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet and vascular thromboxane A2/prostaglandin H2 receptors. Evidence for different subclasses in the rat.
    Masuda A; Mais DE; Oatis JE; Halushka PV
    Biochem Pharmacol; 1991 Jul; 42(3):537-44. PubMed ID: 1830482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.